Results 61 to 70 of about 373,840 (223)

Cardiac surveillance in immune checkpoint inhibitor therapy: Insights from the Essen Cardio‐oncology Registry

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Immune checkpoint inhibitors (ICI) have revolutionized cancer therapy, offering improvements in survival across various malignancies. However, their toxicities pose a major challenge for cardio‐oncology units. Despite their growing importance, data on effectiveness of such specialized units in mitigating ICI‐associated ...
Elias Haj‐Yehia, Lisa Zimmer, Lena Lampe, Dimitra Vlachopoulou, Matthias Totzeck, Tienush Rassaf, Raluca I. Mincu   +6 more
wiley   +1 more source

Jet Injections With Candida Antigen for Wart Treatment: An Alternative Drug Delivery

Pediatric Dermatology, EarlyView.
ABSTRACT Warts are a common pediatric condition caused by human papillomavirus. Immunotherapy is a well‐studied treatment for warts and is classically administered via intralesional injection with a syringe and needle. We report a case of warts in a 12‐year‐old boy who achieved complete resolution following two sessions of pain‐free, and needleless ...
Mary Nan Leath, Theodore Katz, Kimberly Eisenstein   +2 more
wiley   +1 more source

Interferon Tiloron Inductor Usage in Complex Therapy at Patients with Community-Acquired Pneumonia [PDF]

Саратовский научно-медицинский журнал, 2009
The article presents the research findings concerning the importance of changes of the contents in blood serum of interferon gamma (INF-γ), interferon alfa (INF-α), the tumor necrosis factor alfa (TNF-α), interleukin 4 (IL-4), interleukin8 (IL-8) and ...
N.B. Zakharova, G.N. Shemetova, O.A. Kiseleva   +2 more
doaj  

Safety and efficacy of treatment with pegylated interferon alpha-2a with ribavirin in chronic hepatitis C genotype 4

Annals of Hepatology, 2013
The hepatitis C virus (HCV) genotype is an important predictive outcome parameter for pegylated interferon plus ribavirin therapy. Most published therapeutic trials to date have enrolled mainly patients with HCV genotypes 1, 2 and 3. Limited studies have
Juan José Urquijo, Moisés Diago, M.D., Jaume Boadas, Ramón Planas, Ricard Solá, Juan Angel del Olmo, Javier Crespo, José Carlos Erdozaín, María Dolores Antón, Carlos Arocena, Dolores Suarez, Josep Giné, Josep M Barrera, Javier Gracia-Samaniego, Ricardo Perez, Blai Dalmau, Miguel Montoro   +16 more
doaj   +1 more source

Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C.

Gastroenterology, 2002
BACKGROUND & AIMS Liver fibrosis is an important prognostic factor in patients with hepatitis C. The effect of pegylated (PEG) interferon alone or its combination with ribavirin on fibrosis has not been established.
T. Poynard, J. Mchutchison, M. Manns, C. Trépo, K. Lindsay, Z. Goodman, M. Ling, J. Albrecht   +7 more
semanticscholar   +1 more source

Role of RIPK1/RIPK3/MLKL signalling pathway in sepsis‐associated acute kidney injury

Experimental Physiology, EarlyView.
Abstract Sepsis‐associated acute kidney injury (SA‐AKI) is a common clinical syndrome in critically ill patients, and its high mortality rate is closely related to complex pathological mechanisms. Existing studies have shown that the pathophysiological process of SA‐AKI involves complex multi‐mechanism interactions, including an uncontrolled systemic ...
Huijun Yin, Jingyi Wang, Huirong Han
wiley   +1 more source

Polineuropatia desmielinizante inflamatória crônica pós-tratamento com interferon peguilado alfa 2b em um paciente co-infectado HIV/HCV: relato de caso Chronic inflammatory demyelinating polyneuropathy after treatment with pegylated interferon alpha 2b in a patient with HIV/HCV coinfection: case report

Revista da Sociedade Brasileira de Medicina Tropical, 2010
A polineuropatia desmielinizante inflamatória cônica possui forte associação com a infecção pelo HIV e HCV. Uma rara associação entre PDIC e o tratamento da hepatite C com interferon peguilado alfa foi descrita recentemente.
Bil Randerson Bassetti, Eduardo Sturzeneker Trés, Jovana Gobbi Marchesi Ciríaco, Lauro Ferreira Silva Pinto Neto   +3 more
doaj   +1 more source

Neutrophil Extracellular Traps in Atherosclerosis and Cardiovascular Disease

MedComm, Volume 7, Issue 10, October 2026.
NETs as integrated effectors in the atherosclerotic cardiovascular disease continuum. Activated neutrophils release NETs that promote endothelial injury, thrombo‐inflammation, and plaque destabilization throughout atherosclerotic disease progression. Created with BioRender.com.
Ji Zhang, Fangjiaqi Wei, Mengdi Qu, Yuwen Shao, Tingye Xu, Darko Stojkov, Hans‐Uwe Simon, Ben Huang, Changhong Miao, Hao Zhang   +9 more
wiley   +1 more source

Myasthenia Gravis and Thymoma

Muscle &Nerve, Volume 74, Issue 4, Page 1156-1173, October 2026.
ABSTRACT Thymoma is the most common tumor of the anterior mediastinum. Approximately 20%–30% of patients with a thymoma develop myasthenia gravis (MG), and an additional one third may possess positive acetylcholine receptor (AChR) antibodies without MG.
Benjamin Claytor, Lukas Delasos, Daniel P. Raymond, Erik Seroogy, Jason Lempel, Yuebing Li   +5 more
wiley   +1 more source

Systemic Interferon Alfa in Multiple Sclerosis

Archives of Neurology, 1989
To the Editor. —We wish to comment on the conclusions reached by Panitch 1 in his follow-up study of patients treated with subcutaneous interferon alfa. Panitch notes that patients treated with interferon alfa experienced a reduction in attack frequency from 1.33 per year to 0.47 per year over a mean follow-up of four years.
Weinshenker, BG, Ebers, G
openaire   +2 more sources